NOVADIP Biosciences S.A.

NOVADIP Biosciences S.A. is a Belgium-based clinical-stage biopharmaceutical company that aims to revolutionize tissue regeneration and healing. Founded in 2013, Novadip is focused on developing and commercializing innovative regenerative tissue products for treating bone defects and injuries. Their lead allogeneic product, NVD-X3, stands out for its matrix containing multiple bioactive factors, enabling accelerated tissue healing in a single treatment. Additionally, the company is working on NVD-003, an autologous therapy to address congenital pseudarthrosis of the tibia (CPT), a rare pediatric bone condition, with the potential to save limbs and restore mobility. Novadip's commitment to impactful innovation has attracted significant attention, evidenced by their recent €24.00M Series B investment in November 2022. This round saw backing from prominent investors including New Science Ventures, Fund+, INVESTSUD, VIVES Funds, CR-CP Life Science Fund, the SRIW Life Sciences, Olivier van der Rest, Pierre Drion. Novadip's unique 3M³ tissue regeneration technology platform and its focus on critical medical needs position it as a promising player in the biotechnology and healthcare industries, making it a compelling prospect for potential investors seeking impact-driven opportunities.